Radar · Immunotherapy in San Diego
Best Immunotherapy Companies in San Diego, United States
The 79 best Immunotherapy companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Halozyme.
By Riya SenguptaFinancials
79companies tracked
$5.9Bdisclosed funding
0unicorns
60have raised
FLIAR INTELLIGENCE · IMMUNOTHERAPY × SAN DIEGO
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
69%cloud-native stacks
2025funding peak (by rounds)
2017median founding year
42median Fliar Index™
2.1Mcombined LinkedIn audience
95%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Immunotherapy companies in San Diego
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Developer of drug delivery technologies for the treatment of various diseases | $1.3B | 46 mo ago | Public | 373 373 → 536 (+44%) · sector median +7% | Helen Torley CEO & President | 715 patents Enabling subcutaneous delivery of biologics via hyaluronidase and advanced injector devices | — |
| 2 | Ambrx Developer of Antibody drug conjugates to treat cancers, metabolic disorders and cardiovascular disorders | $346M | 67 mo ago | Acquired | 79 | Lawson Macartney President & Ceo | 1,276 patents Protein engineering and antibody-drug conjugates for therapeutic biologics | — |
| 3 | Capstan Therapeutics Developer of cell therapies for a broad range of diseases | $340M | 27 mo ago | Acquired | 75 | Laura Shawver CEO | — | — |
| 4 | Poseida Therapeutics Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | $324M | 34 mo ago | Acquired | 259 | — | 426 patents Patents concentrated in chemistry & materials | — |
| 5 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | Public | 949 | Henry Ji Co-Founder & CEO | 1,073 patents Targeted antibody-drug conjugates and resiniferatoxin-based therapies for cancer and neurodegeneration | — |
| 6 | BlossomHill Therapeutics Provider of the drug for the treatment of oncology and autoimmune disorders 55Funding top 20%Patents top 21%Innovation top 23%Moat top 26% All 7 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 23% Moattop 26% Newsbottom 42% Globalbottom 42% Marketbottom 34% Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $260M | 6 mo ago | Series B | 14 | — | 133 patents Design of macrocyclic kinase inhibitors targeting KRAS, EGFR, and related oncogenic pathways | 3 job openings |
| 7 | PaxVax Oral vaccines against infectious diseases such as cholera, bird flu, HIV & others. | $212M | 126 mo ago | Acquired | 138 | — | 27 patents Adenoviral vector vaccine platforms and spray‑drying formulation technologies for infectious disease vaccines | — |
| 8 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 3 mo ago | Acquired | — | Ken Song CEO | — | — |
| 9 | VelosBio Developer of therapeutic solutions for the treatment of cancer | $204M | 71 mo ago | Acquired | 30 | David Johnson CEO | 55 patents Targeted cancer therapeutics using ROR1-specific antibody‑drug conjugates and bispecific antibodies | — |
| 10 | Artiva Developer of therapeutics for autoimmune diseases and cancer | $198M | 64 mo ago | Public | 15 | — | 6 patents Architectural floor lighting fixtures with arch-shaped multi‑light designs | — |
| 11 | Solve Therapeutics Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment 55Funding top 16%Moat top 40%Global top 45%Market bottom 49% All 5 signals ▾Fundingtop 16% Moattop 40% Globaltop 45% Marketbottom 49% Talentbottom 49% Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 55/100 | $195M | 7 mo ago | Series D | — | Dave Johnson Founder & CEO | — | — |
| 12 | Shoreline Biosciences Developer of cell-based therapeutic solutions for cancer treatment | $183M | 55 mo ago | Series B | 98 | Dan Kaufman Co-Founder | — | — |
| 13 | Janux Therapeutics Developer of immunotherapeutics for the treatment of cancer | $181M | 62 mo ago | Public | 59 59 → 121 (+105%) · sector median +7% | David Campbell President | 170 patents Bispecific T‑cell‑engaging antibodies and cleavable linkers for tumor antigen targeting | — |
| 14 | Turnstone Biologics Developer of oncolytic viral immunotherapies for cancer treatment | $172M | 59 mo ago | Acquired | 80 | John Bell Co-Founder | 61 patents Engineered tumor-infiltrating lymphocytes and ex vivo T‑cell expansion for cancer immunotherapy | — |
| 15 | BioAtla Developer of immunotherapies for cancer using active biologics platform | $162M | 71 mo ago | Public | 41 41 → 35 (-15%) · sector median +7% | Jay Short Chairman | 698 patents Therapeutic antibodies and engineered proteins for targeted cancer and aging cell treatments | — |
| 16 | Lassen Therapeutics Developer of therapeutics to treat cancer | $116M | 30 mo ago | Series B | 6 | Mark Barrett Founder | — | — |
| 17 | MBrace Therapeutics Provider of a technology platform for the development of antibody-drug conjugate to treat cancer | $110M | 31 mo ago | Series B | — | Isan Chen Co-Founder & CEO | — | — |
| 18 | Adcentrx Therapeutics Developer of next-generation targeted therapies for cancer | $101M | 30 mo ago | Series A | 35 | — | — | — |
| 19 | IconOVir Developer of cancer therapeutics using the oncolytic virus | $97M | 36 mo ago | Series B | 35 | Mark Mccamish President and CEO | — | — |
| 20 | AnaptysBio Developer of immunology therapeutics for cancer and inflammatory diseases | $86M | 131 mo ago | Public | 101 101 → 74 (-27%) · sector median +7% | — | 326 patents Therapeutic antibodies/modulators targeting immune checkpoints and cytokine receptors for inflammation | — |
| 21 | Aspyrian Therapeutics Photoimmunotherapy to treat Head and Neck Cancer. | $83M | 107 mo ago | Acqui-Hired | 36 | — | — | — |
| 22 | Cidara Therapeutics Developer of novel anti-infectives for infectious diseases (bacterial and fungal) | $78M | 19 mo ago | Acquired | 90 90 → 48 (-47%) · sector median +7% | Jeff Stein CEO | 275 patents Patents concentrated in health & consumer products | — |
| 23 | Fate Therapeutics Developer of cellular immuno-therapeutics for the treatment of cancer and immune disorders | $78M | 71 mo ago | Public | 181 181 → 227 (+25%) · sector median +7% | Scott Wolchko President & CEO | 606 patents Patents concentrated in chemistry & materials | 2 job openings |
| 24 | Tr1X Developer of T cell-based products to treat autoimmune and inflammatory diseases | $75M | 14 mo ago | Series A | 7 | David Vries Co-Founder | 35 patents Engineered IL-10‑secreting CAR‑CD4+ T cell immunotherapies for cancer treatment | — |
| 25 | OncoSec Medical Developer of intratumoral immunotherapies to harness the body's immune system to fight cancer | $69M | 90 mo ago | Acquired | 26 | — | 148 patents Cancer immunotherapy response biomarkers and electroporation-based gene delivery technologies. | — |
| 26 | Bird Rock Bio Antibody therapeutics to G-Protein Coupled Receptors targets validated with small molecules | $63M | 113 mo ago | Acquired | 14 | — | — | — |
| 27 | Tracon Pharma Developer of antibody therapeutics for the treatment of cancer and fibrotic diseases | $55M | 69 mo ago | Deadpooled | 17 | — | — | — |
| 28 | Primmune Therapeutics Developer of immunotherapies for treating cancer 42Funding top 21%Talent top 28%Product top 35%Innovation top 38% All 8 signals ▾Fundingtop 21% Talenttop 28% Producttop 35% Innovationtop 38% Moattop 39% Techbottom 40% Globalbottom 36% Marketbottom 26% Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) Talent: Analyst team rating 4/5 · 4 named leaders on record rank vs industry peers · Fliar Intelligence Index 42/100 | $47M | 4 mo ago | Series B | 9 | Stephen Webber Co-Founder | — | — |
| 29 | Phanes Therapeutics Developer of therapeutic solutions for treating immuno-oncology and eye disease | $40M | 60 mo ago | Series B | 28 | Ming Wang President and CEO | 205 patents Therapeutic antibodies targeting immune checkpoints and tumor-associated antigens | — |
| 30 | Receptos Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $36M | 172 mo ago | Acquired | 68 | — | 254 patents Sphingosine‑1‑phosphate receptor modulators for autoimmune disease therapeutics | 1 partnership |
| 31 | Patara Pharma Immunomodulators (mast cell stabilizers) for allergic & inflammatory diseases. | $34M | 116 mo ago | Deadpooled | — | William Gerhart CEO and Founder | — | — |
| 32 | Calidi Biotherapeutics Developer of gene therapies for the treatment of cancer and other indications | $34M | 22 mo ago | Public | 29 29 → 31 (+7%) · sector median +7% | Megan Camaisa Co-Founder | 47 patents Oncolytic viral therapies using cell carriers and engineered smallpox vaccine platforms | 1 launch |
| 33 | Equillium Developer of therapies for treating autoimmune and inflammatory disorders | $30M | 10 mo ago | Public | 36 36 → 38 (+6%) · sector median +7% | Daniel Bradbury Co-Founder & CEO | 33 patents CD6‑targeted antibody therapeutics for autoimmune and inflammatory diseases | — |
| 34 | Vironexis Biotherapeutics Developer of AAV-delivered T-cell immunotherapies for the treatment of cancer | $26M | 21 mo ago | Seed | — | Timothy Cripe Co-Founder | 15 patents AAV-based gene therapy vectors targeting metastatic cancer prevention and treatment | — |
| 35 | MabVax Human monoclonal antibodies and vaccines for the diagnosis and treatment of various cancers. | $21M | 97 mo ago | Public | 6 | David Hansen President and CEO | — | — |
| 36 | Adamis Pharmaceuticals Developer of therapeutics for treating respiratory disease and allergy | $16M | 76 mo ago | Public | 15 | — | 140 patents Injection devices and drug delivery formulations for emergency and therapeutic applications | — |
| 37 | RyboDyn Developer of immunotherapies for the treatment of cancer 21Talent top 28%Funding top 37%Global bottom 48%Market bottom 15% All 4 signals ▾Talenttop 28% Fundingtop 37% Globalbottom 48% Marketbottom 15% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 3 mo ago | Seed | 3 | Kerry Wilson Co-Founder | — | — |
| 38 | Abintus Developer of in vivo immune cell therapy | $14M | 46 mo ago | Series B | 13 | Carlos Ibanez Founder | — | — |
| 39 | VLP Biotech Developing innovative vaccines and custom recombinant proteins using proprietary platform | $10M | 144 mo ago | Funding Raised | 15 | Dave Milich CEO | — | — |
| 40 | GRI Bio Small molecules targeting the regulation of Natural killer T cells to treat liver diseases. | $10M | 91 mo ago | Public | 5 | — | — | — |
| 41 | PDI Therapeutics Antibody inhibitors to a specific protein disulfide isomerase to improve recognition of tumor cells by the… | $10M | 121 mo ago | Series A | — | Jay Lichter Managing Partner | — | — |
| 42 | Luxvitae Therapeutics Developer of therapeutics for multiple diseases | $8M | 19 mo ago | Series A | — | Mathew Patt Founder | — | — |
| 43 | Decoy Biosystems Developer of small molecule-based immunotherapeutic solutions for the treatment of cancer | $6M | 78 mo ago | Series A | 2 | Michael Newman Founder & CEO | 40 patents Live bacterial therapeutics for treating infections and cancer | — |
| 44 | Toragen Developer of therapeutics targeting oncogenic viruses | $5M | 44 mo ago | Seed | 7 | Andrew Sharabi Founder | 12 patents Pharmaceutical rimantadine salt formulations for cancer and HPV lesion treatment | — |
| 45 | Femta Pharmaceuticals Develops therapeutic monoclonal antibodies | $4M | 188 mo ago | Deadpooled | — | Stephen Keane CEO | — | — |
| 46 | INmuneBIO Provider of immunotherapeutics for the treatment of multiple conditions | $3M | 17 mo ago | Public | 11 11 → 16 (+45%) · sector median +7% | Raymond Tesi CEO & CMO | — | — |
| 47 | Batu Biologics Content creation, digital marketing, and business growth strategies provider | $3M | 101 mo ago | Seed | 3 | — | 37 patents Cancer immunotherapy via oncolytic viruses and anti‑angiogenic endothelial vaccines | — |
| 48 | RIFT Biotherapeutics US-based, early stage biopharma developing therapeutic antibodies for oncology | $2M | 110 mo ago | Deadpooled | 3 | — | — | — |
| 49 | Multimeric Biotherapeutics Developing FortiVac vaccine platform for strong CD8+ T cell responses | $2M | 129 mo ago | Funding Raised | — | Marc Hertz Founder & Chairman | — | — |
| 50 | Antlia Bioscience Developer of peptide-based therapeutic solutions for the treatment of chronic heart failure | $207K | 21 mo ago | Seed | 3 | Nigel Shankley Co-Founder | — | — |
Top 12 Immunotherapy companies in San Diego
#1
Acquired · San Diego, California · founded 2024$206.2Mraised▾
Acquired · San Diego, California · founded 2024
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Growth
top 38%News
top 48%Moat
top 48%Talent
bottom 49%Tech
bottom 38%Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series E (Mar 2026)
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 8 tracked, 2 types) · +0% YoY · Top themes: M&A
Audience (LinkedIn): 9k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Mar 2026Series E$505M
- Sep 2024Series D$370M
Founders & team
Investors
Venrock, Fairmont, TCG Crossover, VenBio, Foresite Capital, Third Rock Ventures
Tech stack
CloudflareCloudflare Bot ManagementDreamhostGoogle Font ApiHttp/3Jquery
#2
Series B · San Diego, California · founded 2020 · 14 employees$259.6Mraised▾
Series B · San Diego, California · founded 2020 · 14 employees
Provider of the drug for the treatment of oncology and autoimmune disorders. The company is involved in drug design and development based on small molecules.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 23%Moat
top 26%News
bottom 42%Global
bottom 42%Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (Nov 2025)
Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Innovation: 133 patents (top 21% of patent-holders) · 133 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 9k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Principal Programmer, Statistical Programming, Director/Senior Director, Medical Affairs
Funding rounds
- Nov 2025Series B$84.2M
- Dec 2023Series B$100M
- Mar 2021Series A$71M
Investors
Cormorant Asset Management, Orbimed, Vivo Capital, Colt Ventures, Plaisance Capital Management, H&D Asset Management
#3
Series D · San Diego, California · founded 2021$195Mraised▾
Series D · San Diego, California · founded 2021
Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment. The company focuses on advancing antibody-based therapeutics to address unmet medical needs. It refines a chemistry platform while developing targeted radionuclide therapeutics. The company evaluates companion radiodiagnostics for use with other types of targeted cancer therapeutics.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 16%Moat
top 40%Global
top 45%Market
bottom 49%Talent
bottom 49%Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series D (Nov 2025)
Moat: Soonicorn · 10 curated direct competitors tracked
Global: Investors from 3 countries beyond United States
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Nov 2025Series D$120M
- Dec 2024Series C$75M
Founders & team
Investors
Yosemite, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck
#4
Series B · San Diego, California · founded 2017 · 9 employees$46.8Mraised▾
Series B · San Diego, California · founded 2017 · 9 employees
Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Talent
top 28%Product
top 35%Innovation
top 38%Moat
top 39%Tech
bottom 40%Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) · Last round Series B (Jan 2026)
Talent: Analyst team rating 4/5 · 4 named leaders on record · 4 C-suite/founder profiles curated
Product: 3 distinct product lines · Company stage: Series B
Funding rounds
- Jan 2026Series B$8.6M
- Nov 2021Series A$8.4M
- Jan 2021Series A$4M
- Oct 2020Series A$27.4M
Founders & team
Investors
CAM Capital, BioBrit, BioRock Ventures, Bioqube Ventures, Polaris Partners, Samsara BioCapital
Tech stack
WordpressMysqlPhpDownload MonitorContact Form 7Yoast Seo
#5
Seed · San Diego, California · founded 2022 · 3 employees$14Mraised▾
Seed · San Diego, California · founded 2022 · 3 employees
Developer of immunotherapies for the treatment of cancer. The company has developed antigen discovery and validation platform to create a transformative medicines for patients with cancer.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Talent
top 28%Funding
top 37%Global
bottom 48%Market
bottom 15%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Seed (Mar 2026)
Global: Investors from 2 countries beyond United States
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Mar 2026Seed$10M
- Jan 2025Seed$4M
- Jun 2023Seed—
Founders & team
Investors
EvoNexus, Genedant, SeaX Ventures, SOSV, Swell
#6
Public · San Diego, California · founded 1989 · 949 employees$281.6Mraised▾
Public · San Diego, California · founded 1989 · 949 employees
Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases. The company’s lead products are multiple biosimilars and bio better antibodies as well as clinical CAR-T therapies targeting solid tumors. Also, has a portfolio of immuno-oncology antibody programs targeting EGFR, TNF-alpha, CD 25, and IGE. Its lead CAR-T cell therapies are against the carcinoembryonic antigen and prostate-specific membrane antigen.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 20%Patents
top 20%Market
top 26%Moat
top 30%Innovation
top 32%Growth
top 45%Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) · Last round Post IPO (Apr 2025)
Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 · Latest publication 2026
Market: 949 employees (top 9% of Immunotherapy) · Revenue ~$62.8M · ~13% of tracked Immunotherapy revenue (13 cos, FY2026)
Funding rounds
- Apr 2025Post IPO$47.4M
- Sep 2018Conventional Debt—
- Jun 2018Post IPO$150M
- Nov 2016Venture Debt$50M
Founders & team
Investors
Aisling Capital, Yuhan Corporation, Hercules Capital, Ally Bridge Group, FREJOY Investment Management, Beijing Shijilongxin Investment
Tech stack
WordpressMysqlPhpTwenty FourteenYoast SeoNginx
#7
Series A · San Diego, California · founded 2018 · 7 employees$75Mraised▾
Series A · San Diego, California · founded 2018 · 7 employees
Developer of T cell-based products to treat autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of cell therapy products to restore immune tolerance, with the potential to treat autoimmune and inflammatory diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Apr 2025Grant (prize money)$8M
- 2024Grant (prize money)$4M
- Jan 2024Series A$75M
Founders & team
Investors
The Column Group, Neva SGR, Alexandria, CIRM
#8
Public · San Diego, California · founded 2017 · 36 employees$30Mraised▾
Public · San Diego, California · founded 2017 · 36 employees
Developer of therapies for treating autoimmune and inflammatory disorders. The lead product, itolizumab is a treatment for multiple severe immuno-inflammatory disorders, including graft-versus-host disease, uncontrolled moderate to severe asthma, and SLE / lupus nephritis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers
Activity: 1 awards announced in 12 mo
Funding rounds
- Aug 2025Post IPO$30M
Founders & team
Investors
ADAR1 Capital Management, Janus Henderson Investors, Adage Capital Management, Coastlands Capital, Woodline Partners, Alumni Ventures
Tech stack
CloudflareDocusignFancyboxGoogle AnalyticsGoogle Font ApiHsts
#9
Acquired · San Diego, California · founded 2013 · 90 employees$78.4Mraised▾
Acquired · San Diego, California · founded 2013 · 90 employees
Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 10k LinkedIn followers
Funding rounds
- Nov 2024Post IPO$105M
- Apr 2024Post IPO$240M
- Sep 2019Post IPO$9M
- May 2018Post IPO$1.6M
Founders & team
Investors
Great Point Partners, BB Biotech, Broadfin Capital, Investopedia, Venrock, RA Capital Management
Tech stack
WordpressMysqlPhpMaterial Design LiteWpbakeryYoast Seo
#10
Acquired · San Diego, California · founded 2021 · 75 employees$340Mraised▾
Acquired · San Diego, California · founded 2021 · 75 employees
Developer of cell therapies for a broad range of diseases. The company's technology comprises targeted lipid nanoparticles (tLNPs), CAR-based immunotherapy, and nucleic acid drug delivery to develop treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders.
Funding rounds
- Mar 2024Series B$175M
- Jun 2022Series A$102M
- Nov 2021Seed$63M
Founders & team
Investors
RA Capital Management, Forbion, Johnson & Johnson Innovation – JJDC, Mubadala, Perceptive Advisors, Sofinnova Investments
#11
Public · San Diego, California · founded 2018 · 29 employees$33.8Mraised▾
Public · San Diego, California · founded 2018 · 29 employees
Developer of gene therapies for the treatment of cancer and other indications. It is a clinical-stage immuno-oncology company developing stem cell-based platforms to deliver oncolytic viruses that target solid tumors and enhance immune responses against metastatic cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Jul 2024Post IPO$1M
- Mar 2024Post IPO$3.5M
- Jan 2024Post IPO$1M
- Nov 2023Post IPO$195K
Founders & team
Investors
Wong & Partners, CIRM, Jackson Investment Group, Won & Partners
Tech stack
Apple Icloud MailCloudflareDocusignFancyboxGodaddyGoogle Analytics
#12
Public · San Diego, California · founded 1999 · 373 employees$1.3Braised▾
Public · San Diego, California · founded 1999 · 373 employees
Developer of drug delivery technologies for the treatment of various diseases. The company's lead product is ENHANZE drug delivery technology, based on the proprietary enzyme rHuPH20, which is used to facilitate the delivery of injected drugs and fluids. Also, it offers Hylenex recombinant an endoglycosidase indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 24k LinkedIn followers
Activity: 2 partnerships (incl. Vertex Pharmaceuticals) announced in 12 mo
Funding rounds
- Aug 2022Post IPO$625M
- Nov 2019Post IPO$388.5M
- Jan 2016Venture Debt$150M
- Jan 2014Venture Debt$20M
Founders & team
Investors
Oxford Finance, SVB, Athyrium Capital Management, BioPharma Funds, Roche, Third Security
Tech stack
All In One SeoApache Http ServerApple Icloud MailBugherdCdnjsCloudflare
Funding & investor landscape
$5.9Btotal disclosed funding
59companies funded
243disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Ken Song
CEO · Candid Therapeutics
Dave Johnson
Founder & CEO · Solve Therapeutics
Stephen Webber
Co-Founder · Primmune Therapeutics
James Appleman
Co-Founder & CSO · Primmune Therapeutics
Kerry Wilson
Co-Founder · RyboDyn
Ashley Woodfin
Co-Founder · RyboDyn
Henry Ji
Co-Founder & CEO · Sorrento Therapeutics
David Vries
Co-Founder · Tr1X
Maria Roncarolo
Co-Founder · Tr1X
Daniel Bradbury
Co-Founder & CEO · Equillium
Jeff Stein
CEO · Cidara Therapeutics
Laura Shawver
CEO · Capstan Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,146,706 docs
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 55% → 62% across 2008–2026.
top research entities
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
leading researchers
Sarkar, Subhankar · F. Stephen Hodi · Jedd D. Wolchok · Michael A. Postow · Thomas Powles · Yan-Ruide Li · Abdullah Esmail · Julie R. Brahmer
▲
Breakthroughs3,482 · 25%
▲ 22%→25% share
▲1.1× share momentum0 median citations89% since 2021mostly methods-led
Breakthroughs are rising (22%→25% of field), led by Immune system.
rising sub-themes (early→recent)
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
Newly emergingBreast cancer 0→90 · Reprogramming 0→86 · Flow cytometry 0→44
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements6,585 · 47%
▼ 51%→47% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Advancements are cooling (51%→47% of field), led by Immune system.
rising sub-themes (early→recent)
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
Newly emergingTranscriptome 0→108 · Retrospective cohort study 0→62 · Phases of clinical research 0→59
Landmark Improved Survival with Ipilimumab in Patients with Metastatic Melanoma · 15,037 cites
▼
Concerns2,356 · 17%
▲ 16%→17% share
▲1.1× share momentum0 median citations87% since 2021mostly empirical
Concerns are rising (16%→17% of field), led by Immune system.
rising sub-themes (early→recent)
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Newly emergingMultiple myeloma 0→54 · MEDLINE 0→49 · Refractory (planetary science) 0→39
Landmark PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer · 30,895 cites
RESEARCH HOTSPOTS · United States
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1049 · +0.47
New York931 · +0.44
SF Bay Area496 · +0.50
Philadelphia473 · +0.46
Chicago379 · +0.45
Los Angeles309 · +0.48
Atlanta261 · +0.45
San Diego234 · +0.47
Seattle195 · +0.48
Pittsburgh179 · +0.43
PATENT SIGNAL · United States
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
10,389 filings4,528 assigneespeak 1314/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST222
Common questions
How many Immunotherapy companies are there in San Diego, United States?
Radar tracks 79 indexable Immunotherapy companies headquartered in San Diego, United States that meet our profile-completeness bar.
What is the total funding raised by Immunotherapy companies in San Diego, United States?
The Immunotherapy companies in San Diego, United States on this list have raised a combined $5.9B in disclosed equity funding across 59 funded companies.
Which is the highest-funded Immunotherapy company in San Diego, United States?
Halozyme is the highest-funded Immunotherapy company in San Diego, United States, with $1.3B in disclosed equity funding.
How many Immunotherapy companies in San Diego, United States are funded?
59 of the 79 Immunotherapy companies in San Diego, United States on this list have disclosed at least one equity funding round.
How many Immunotherapy unicorns are there in San Diego, United States?
None of the Immunotherapy companies in San Diego, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in San Diego, United States Immunotherapy companies?
The most active investors in San Diego, United States Immunotherapy companies on this list include HHS, Janus Henderson Investors, Venrock, Orbimed, Polaris Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.